Glofitamab and obinutuzumab (GLOBIN) as first-line therapy for patients with high-tumor burden follicular lymphoma: First results of a multicenter phase II trialReid W. Merryman, Joshua Brody, Gottfried von Keudell et al.|Blood|2025Cited by 0
Rituximab and epcoritamab as first-line therapy for patients with high-tumor burden follicular lymphoma: Results of a multicenter phase II trialReid W. Merryman, Yazeed Sawalha, Rosario Tringale et al.|Blood|2025Cited by 0